
REDUCING AN UNPRECEDENTED RISE IN SYPHILIS RATES BY ENHANCED SCREENING & TESTING

SYPHILIS IN SOUTH DAKOTA

2021 DATA Provisional data as of 3.1.22		
ADULT SYPHILIS	CONGENITAL / SYPHILITIC STILLBIRTHS	
874 Infections Reported 622% Increase from 2020	16 Congenital and 4 Syphilitic Stillbirths 300% Increase from 2020	
1,050% Increase from 5-Year Median	700% Increase in 5-Year Median	



	93% heterosexual exposure 45% history of other STIs 45% history of incarceration 75% American Indian 59% Reported age range of 25-39 years-old		36% sex while intoxicated 27% used IV drug use 21% cases reported among an institutionalized population				
Th	The SD Department of Health asks providers to perform enhanced screenings						
in	select settings and populations.						
SC	CREEN						
PR	RENATAL CARE PROVIDERS						
	 All pregnant women should be screened for syphilis three At first prenatal appointment or at time of initial pregnancy diagnosis if concerned for poor follow up All pregnant women delivering a stillbirth (gestational agents) 		At 28 weeksAt delivery				
ΕN	MERGENCY DEPARTMENT / URGENT CARE PR	e OV	IDERS / DRIMARY CARE DROVIDERS				
	All pregnant women Men who have sex with men Individuals with HIV infection Individuals with multiple sex partners, or a partner who has multiple sex partners		Individuals incarcerated IV drug users and/or substance abuse Individuals with a history of sexually transmitted infections				
In an effort to stop congenital syphilis SD-DOH recommends enhancing syphilis screening to emergency room departments and urgent care. In 2021 South Dakota mothers associated with congenital/syphilitic stillbirths had insufficient, late, or no prenatal care, however, some of those same women and/or their partners were seen in emergency rooms and urgent care for reasons other than prenatal care. Screening women of reproductive age (15-45 years) and sex partners to women of reproductive age can reduce congenital syphilis.							
Р	HYSICAL EXAMINATION						
	If the history or serologic tests are suggestive AND/OR						
N	/IEDICAL HISTORY						
	Previous STI history & treatment Sexual partner with STIs Symptom history: Particularly symptom history of sores on the genitals, anus, or mouth or a rash on the body, especially on the palms of the		Sexual orientation Number of sex partners Injection Drug Use				



hands or soles of the feet.

TREAT

Immediately treat infected individuals, individuals with signs/ symptoms, and individuals who report exposure to syphilis, even before confirmatory test results return. Additionally, if tests are negative, but the clinician is suspicious of syphilis, the patient should be treated for syphilis.

RISK CATEGORY RECOMMENDED REGIMEN		ALTERNATIVES	
Early (primary, secondary, or early latent)	benzathine penicillin G 2.4 million units IM in a single dose	Doxycycline 100 mg orally 2 times/day for 14 days. Pregnant women allergic to penicillin should be desensitized and treated with penicillin G.	
Late Latent or unknown duration	benzathine penicillin G 7.2 million units total, administered as 3 doses of 2.4 million units IM each at 1-week intervals	Doxycycline 100 mg orally 2 times/day for 28 days. Pregnant women allergic to penicillin should be desensitized and treated with penicillin G.	
Neurosyphilis, ocular syphilis, and otosyphilis	Aqueous crystalline penicillin G 18-24 million units per day, administered as 3-4 million units by IV every 4 hours or continuous infusion, for 10-14 days	procaine penicillin G 2.4 million units IM 1x/day PLUS probenecid 500 mg orally 4x/day, both for 10-14 days	
For children or congenital syphilis See STI Treatment Guidelines, 2021			

The complete list of recommendations on treating syphilis and discussion of alternative therapy in people with penicillin allergy can be found in <u>STI Treatment Guidelines</u>, <u>2021</u>.

POST EVALUATION

- □ People with primary or secondary syphilis should have clinical & serologic evaluation at 6 & 12 months after treatment.
- □ People with HIV infection should have a clinical and serological evaluation for treatment failure at 3, 6, 9, 12, and 24 months.
- □ People with latent syphilis should have quantitative nontreponemal serologic tests repeated at 6, 12, and 24 months.

MANAGEMENT OF PARTNERS

Anyone who has had sexual contact with an individual with syphilis should be notified, examined clinically, receive syphilis serologic testing, and receive treatment based on the following:

- ☐ Sexual contact to a patient with primary/secondary/early latent syphilis:
 - If exposed ≤ 90 days of a diagnosed case, CDC recommends presumptive treatment for early syphilis, even if serologic test results are negative
 - If exposed ≥ 90 days of a diagnosed case, CDC recommends presumptive treatment if serologic test results are not immediately available, and follow-up is uncertain. If serologic tests are positive, treatment should be based on clinical and serologic evaluation and syphilis stage. If serologic tests are negative, no treatment is needed.
- ☐ Sexual contact to a patient with unknown duration or late syphilis:
 - Evaluation & presumptive treatment of contacts exposed within 12 months of first serologic evidence of infection, or re-infection in the case-patient



TESTS

Diagnosis of syphilis requires the use of two tests: a nontreponemal and a treponemal test.

- Nontreponemal Antibody Test: Detect antibodies not specifically directed against the *Treponema pallidum* bacteria. The body produces these antibodies when an individual has syphilis but may also be produced in several other conditions. The tests are highly sensitive, but since they are non-specific, false-positive results can be caused by, for example, IDU, pregnancy, Lyme disease, certain types of pneumonia, malaria, TB, or certain autoimmune disorders, including lupus. Nontreponemal tests include:
 - RPR (Rapid Plasma Reagin): in addition to screening, this test is useful in monitoring treatment for syphilis. It may also be used to confirm the presence of an active infection when an initial examination for treponemal antibodies is positive. For this purpose, the level (titer) of the antibody is measured.
 - VDRL (Venereal Disease Research Laboratory): in addition to blood, this test is primarily performed on CSF to help diagnose neurosyphilis.
- ☐ **Treponemal Antibody Test:** Detect antibodies that specifically target *T. pallidum*. They are highly specific for syphilis, meaning other conditions are unlikely to cause a positive result. However, once a person is infected and these antibodies develop, they remain in the blood for life. Treponemal antibody tests include:
 - FTA-ABS (Fluorescent treponemal antibody absorption): this test is useful after the first 3-4 weeks following exposure. In addition to blood testing, it can be used to measure antibodies to *T. pallidum* in the CSF to help diagnose neurosyphilis.
 - TP-PA (T. pallidum particle agglutination assay): this test is sometimes performed instead of FTA-ABS because it is more specific and has fewer false positives.

- MHA-TP (Micro hemagglutination assay): another confirmatory method; this test is used much less commonly.
- IgG and IgM Enzyme Immunoassays ~ IgG (SYPGN / Syphilis Total Antibody, Serum): is recommended for prenatal screening. Testing for IgM-class antibodies should not be performed during routine pregnancy screening unless clinically indicated.

STAGES OF INFECTION AND CLINICAL DESCRIPTION

- □ **Primary Syphilis:** Classically presents as a single painless ulcer or chancre at the site of infection but can also present with multiple, atypical, or painful lesions.
- Secondary Syphilis: Characterized by localized or diffuse mucocutaneous lesions (e.g., rash such as non-pruritic macular, maculopapular, papular, or pustular lesions), often with generalized lymphadenopathy. Other signs can include mucous patches, condyloma lata, and alopecia. The primary ulcerative lesion may still be present.
- ☐ Early Non-Primary and Non-Secondary Syphilis: A person's initial infection has occurred within the previous 12 months, and there are NO signs or symptoms of primary or secondary syphilis. May fall between primary and secondary, and after the secondary stage.
- □ **Unknown Duration or Late:** Person's initial infection has occurred greater than 12 months previously or in which there is insufficient evidence to conclude that infection was acquired during the previous 12 months.

SYPHILIS MANIFESTATION

Neurosyphilis, ocular syphilis, and otosyphilis should be considered in the differential diagnosis of neurological, ocular, and other signs and symptoms among persons with HIV Infection



- □ Congenital: An infant or child (aged less than 2-years) may have signs such as hepatosplenomegaly, rash, condyloma lata, snuffles, jaundice (nonviral hepatitis), pseudo paralysis, anemia, or edema (nephrotic syndrome and/or malnutrition). An older child may have stigmata (e.g., interstitial keratitis, nerve deafness, anterior bowing of shins, frontal bossing, mulberry molars, Hutchinson teeth, saddle nose, rhagades, or Clutton joints).
- Syphilis Stillbirth: A fetal death that occurs after a 20-week gestation or when the fetus weighs greater than 500g and the mother had untreated or inadequately treated at delivery.

ADEQUATE TREATMENT FOR INFECTED CASE DURING PREGNANCY

- Completion of a penicillin-based regimen, appropriate for stage of infection, initiated 30 or more days before delivery.
- Pregnant women MUST be treated with penicillin. If allergic, she must be desensitized and treated to stage of illness.

INCUBATION PERIOD

- ☐ **Primary**: A chancre typically occurs about 3 weeks (range 10 to 90 days) after exposure and lasts 3 to 6 weeks.
- ☐ **Secondary**: 4 to 8 weeks after onset of the primary chancre.
- □ Neurologic, Ocular, or Otic: Manifestations can occur at any stage of syphilis.
- ☐ Late clinical: Manifestations (tertiary syphilis) generally occur after 15–30 years of untreated infection.

What do Disease Intervention Specialists do?

CASE MANAGEMENT AND PARTNER NOTIFICATION

Disease Intervention Specialists (DIS) follow-up with and provide case management to all physician-diagnosed and/or suspect cases. **Case management includes:**

- ☐ Completing a medical chart review for necessary patient information; for example, diagnostic, demographic, clinical, and known risk history information
- ☐ Conducting client interviews to obtain additional pertinent information, elicit contacts, provide partner notification and disease management for follow-up and prevention
- ☐ Providing STI testing and treatment assistance, for example, arranging transportation
- ☐ Communicating pertinent information that is learned through investigations with the medical provider to assist with the testing and treatment continuum of care

DISEASE INTERVENTION SPECIALIST CONTACT INFORMATION

Contact your local DIS with syphilis questions or if you need assistance contacting a client for testing, treatment, and counseling for syphilis, HIV/AIDS, and other sexually transmitted infections.

Aberdeen 402 S. Main St. Aberdeen, SD 57401-4127 Toll-free: 1-866-805-1007	Mobridge 210 East Grand Crossing, Suite A Mobridge, SD 57601 Toll-free: 1-833-618-2740	Sioux Falls 4101 West 38 th St., Suite 102 Sioux Falls, SD 57106 Toll-free: 1-866-315-9214
Pierre 740 E. Sioux, Suite 107 Pierre, SD 57501-3395 Toll-free: 1-866-229-4927	Rapid City 909 E. St. Patrick, Suite 10 Rapid City, SD 57701 Toll-free: 1-866-474-8221	Watertown 2001 9 th Ave. SW #500 Watertown, SD 57201-4038 Toll-free: 1-866-817-4090
Mitchell 1420 North Main St. Mitchell, SD 57301 605-995-8051	Main office Toll-Free: 800-592-1861	



Additional Resources for Providers

CDC 2021 STI Treatment Guidelines

https://www.cdc.gov/std/treatment-guidelines/default.htm

- ☐ An updated STI Treatment Guidelines mobile app is in development and is expected to launch in the coming months. CDC has an interim, mobile-friendly solution please visit https://www.cdc.gov/std/treatment-guidelines/default.htm for instructions on how to access it.
- ☐ Provider Resources, including wall charts and pocket guide, are available at: https://www.cdc.gov/std/treatment-guidelines/provider-resources.htm
- ☐ A recording of the STI guidelines informational webinar and questions and answers are available at: https://www.cdc.gov/std/treatment/default.htm

STI CLINICAL CONSULTATION SERVICE

https://www.stdccn.org/render/Public

The National Network of STI Clinical Prevention Training Centers offers a *clinical consultation service* intended for licensed healthcare professionals and STI program staff. Submit a clinical consult by going to the above link and entering your online consultation request.

NATIONAL STI CURRICULUM

https://www.cdc.gov/std/training/courses.htm

The *National STI Curriculum* is a free educational website from the University of Washington STI Prevention Training Center. This online modular learning experience addresses the epidemiology, pathogenesis, clinical manifestations, diagnosis, management, and prevention of STIs. It is continuously updated and integrates the most recent STI Treatment Guidelines. Free CME/CNE/CE available.

A Guide for Taking a Sexual History: This booklet guides how to discuss sexual health issues with patients. Available at https://www.cdc.gov/std/treatment/sexualhistory.htm

This publication was supported by Centers for Disease Control and Prevention (CDC) grant number, 6 NH29F0005161-03-04 as a part of an award totaling \$1,000,000.00 with \$0.00 state funding. The views expressed in this written material or publication do not necessarily reflect the official policies of the Centers for how the control of the Centers for his written material or publication do not necessarily reflect the official policies of the Centers for his written material or publication do not necessarily reflect the official policies of the Centers for his written material or publication do not necessarily reflect the official policies of the Centers for his written material or publication do not necessarily reflect the official policies of the Centers for his written material or publication do not necessarily reflect the official policies of the Centers for his written material or publication do not necessarily reflect the official policies of the Centers for his written material or publication do not necessarily reflect the official policies of the Centers for his written material or publication do not necessarily reflect the official policies of the Centers for his written material or publication do not necessarily reflect the official policies of the Centers for his written material or publication do not necessarily reflect the official policies of the Centers for his written material or publication do not necessarily reflect the official policies of the Centers for his written material or publication do not necessarily reflect the official policies of the Centers for his written material or publication do not necessarily reflect the official policies of the Centers for his written material or publication do not necessarily reflect the official policies of the Centers for his written material policies of the Cente

